Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.37 |
| ▸ | MBOAT4 | Q96T53 | 2/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | QPCT | Q16769 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23915452 | 0.90 | MAPT (0.43) | ALDH1A1MAPTLMNAVCAM1RXFP1 | |
| SCHEMBL23915453 | 0.83 | MAPT (0.51) | ALDH1A1MAPTLMNAVCAM1 | |
| SCHEMBL23914596 | 0.82 | KDM4E (0.40) | ALDH1A1MAPTMBOAT4AAK1QPCT | |
| SCHEMBL23914956 | 0.81 | ALDH1A1 (0.43) | ALDH1A1MAPTLMNAHTT | |
| SCHEMBL23914981 | 0.80 | MAPT (0.48) | ALDH1A1MAPTLMNAVCAM1SMN1; SMN2 | |
| SCHEMBL23909063 | 0.80 | VCAM1 (0.38) | ALDH1A1MAPTLMNAVCAM1RXFP1 | |
| SCHEMBL1511848 | 0.78 | ALDH1A1 (0.46) | ALDH1A1MAPTLMNAVCAM1HTT | |
| SCHEMBL23909023 | 0.77 | MEN1 (0.42) | ALDH1A1MAPTVCAM1SMN1; SMN2HTT | |
| SCHEMBL19606264 | 0.73 | MAPT (0.50) | ALDH1A1MAPTVCAM1RXFP1HTT | |
| SCHEMBL2338470 | 0.73 | ALDH1A1 (0.44) | ALDH1A1MAPTVCAM1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | ALDH1A1 944/4885MAPT 4876/4885LMNA 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.